[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577085":3},{"organization":4,"outcomesModule":7,"designInfo":16,"detailedDescription":11,"studyPopulation":19,"armGroups":20,"interventions":25,"overallOfficials":11,"centralContacts":31,"locations":36,"responsibleParty":49,"collaborators":11,"id":51,"slug":11,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":11,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":11,"maxAge":11,"enrollmentInfo":58,"targetDuration":11,"studyType":61,"phases":11,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":39,"whyStopped":11,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},{"fullName":5,"class":6},"Eisai Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Number of Participants With Adverse Drug Reactions",null,"Up to 1 year",[14],{"measure":15,"description":11,"timeFrame":12},"Percentage of Participants With Best Overall Response (BOR) Based on Physician's Assessment",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":17,"timePerspective":18,"maskingInfo":11},"COHORT","PROSPECTIVE","Participants with FGFR2 fusion positive unresectable biliary tract cancer with prior chemotherapy who will receive Tasfygo tablet as per daily practice and package insert will be enrolled.",[21],{"label":22,"type":11,"description":11,"interventionNames":23},"Tasfygo tablet 35 milligrams (mg)",[24],"Other: No Intervention",[26],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"OTHER","No Intervention","This is a non-interventional study.",[22],[32],{"name":33,"role":34,"phone":11,"phoneExt":11,"email":35},"Eisai Inquiry Service","CONTACT","eisai-chiken_hotline@hhc.eisai.co.jp",[37],{"facility":38,"status":39,"city":40,"state":11,"zip":11,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":11},"#Eisai Trial Site 1","RECRUITING","Tokyo","Japan","JP",{"type":44,"coordinates":45},"Point",[46,47],139.69171,35.6895,{"lat":47,"lon":46},{"type":50,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100577085",false,"NCT06793709","A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy","Post-marketing Observational Study of Tasfygo Tablet 35 mg to Evaluate the Safety of Tasfygo in Patients With Unresectable Biliary Tract Cancer With FGFR2 Fusion Gene Positivity Who Progressed After Chemotherapy","Inclusion Criteria:\n\n1\\. Participants with unresectable biliary tract cancer with FGFR2 fusion gene positivity who are naïve to Tasfygo tablet and progressed after chemotherapy.\n\nExclusion Criteria:\n\nNot applicable.","ALL",{"count":59,"type":60},60,"ESTIMATED","OBSERVATIONAL","The primary purpose of this study is to investigate the safety of Tasfygo.",[64],"Biliary Tract Cancer",[66,67,68],"Tasfygo","FGFR2 fusion","Cancer","2026-02-25",{"date":71,"type":72},"2026-02-27","ACTUAL",{"date":74,"type":72},"2025-07-10",{"date":76,"type":60},"2032-11-20",{"name":78,"class":6},"Eisai Co., Ltd.",1]